Apomab: Completed Phase II enrollment

Roche disclosed that last quarter it completed enrollment of 50 patients in an open-label Phase II trial evaluating IV Apomab plus rituximab. Biogen Idec Inc. (NASDAQ:BIIB, Cambridge, Mass.) and Roch...